Paul Lammers - 20 Feb 2024 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Director
Signature
/s/Mark Rosenblum, as Attorney-in-Fact
Issuer symbol
SLRX
Transactions as of
20 Feb 2024
Net transactions value
$0
Form type
4
Filing time
22 Feb 2024, 16:16:01 UTC
Previous filing
05 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLRX Stock Option (right to buy) Award $0 +20,500 $0.000000 20,500 20 Feb 2024 Common Stock 20,500 $0.5711 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.